                                                   7
        4-pregnene-16a-methyl-17a-mellow-3,        20-diketone drug synthesis method
         Abstract
 5       The    present     invention    discloses   4-pregnene- I 6a-methyl- 1 7u-mellow-3,
   20-diketone drug synthesis method, comprises the following steps:, comprises the
   following steps: 2-bromo-4-amino-5-pregnene-16ax-methyl-3 p, 17a-glycol-20-ketone,
   and potassium nitrate solution were added to the reaction vessel, controlled the
   stirring speed, raised the temperature of the solution, continued to react; added butyric
10 acid methyl ester solution to react, raised the temperature of the solution, continued to
   react, then added tetrakis (triethyl phosphite) nickel powder, refluxed, reduced the
   temperature of the solution, added the oxalic acid solution, lay up to get hierarchical
   solution, washed with the potassium chloride solution for several times, washed with
   2-butylene-1,4-diacid solution for several times, washed with the p-xylene solution
15 for several times, re-crystallized in the dimethyl sulfone solution, dehydrated with
   dehydration,    got   the    finished   product   4-pregnene-16a-methyl-17a-mellow-3,
   20-diketone drug.

                                                 1
       4-pregnene-16a-methyl-17a-mellow-3,       20-diketone drug synthesis method
         FIELD OF THE INVENTION
         The present invention relates to a method for preparing a pharmaceutical
 5 intermediate which belongs to the field of organic synthesis, more particularly, relates
   to 4-pregnene- I 6a-methyl- 17a-mellow-3, 20-diketone drug synthesis method.
         GENERAL BACKGROUND
         4-pregnene-16u-methyl-17a-mellow-3,     20-diketone drug is a kind of hormone
10 pharmaceutical intermediates. It is used for the production of dexamethasone acetate
   which belongs to adrenal cortical hormone and adrenocorticotropic hormone, it can be
   used for anti-skin mucosal inflammation and allergic reactions, eye ointment can be
   used for the treatment various ophthalmia. However, most of the existing synthesis
   methods are using the mixed solution of chromium oxide and sulfuric acid as one of
15 reactions, chromic oxide results in environmental pollution, sulfuric acid attributes to
   high-risk chemicals factor, and the synthesis method is complicated. Therefore, it is
   necessary to propose a new synthesis method.
         SUMMARY
20       Based on the technical problems of the background technology, the purpose of the
   present invention is to provide 4-pregnene- 16a-methyl- 17a-mellow-3, 20-diketone
   drug synthesis method, comprises the following steps:
         A: 2-bromo-4-amino-5-pregnene-16a-methyl-3p,        17a-glycol-20-ketone, and 1.5
   L potassium nitrate solution were added to the reaction vessel, controlled the stirring
25 speed at 110-150 rpm, raised the temperature of the solution to 40-47 "C , continued to
   react for 60-80 min;
         B: added butyric acid methyl ester solution to react, raised the temperature of the
   solution to 50-56 'C,   continued to react for 30-40min, then added tetrakis (triethyl

                                                       2
   phosphite) nickel powder, refluxed for 30-50min, reduced the temperature of the
   solution to 30-36 0 C, added the oxalic acid solution, lay up for 1-2 hours to get
   hierarchical solution, washed with the potassium chloride solution for several times,
   washed with 2- butylene-1,4-diacid solution for several times, washed with the
 5 p-xylene solution for several times, re-crystallized in the dimethyl sulfone solution,
   dehydrated          with       dehydration,            got     the   finished      product
   4-pregnene- 16a-methyl- 17a-mellow-3, 20-diketone drug.
          Preferably, the potassium nitrate solution has a mass fraction of 10-16%.
          Preferably, the mass fraction of the butyric acid methyl ester solution is 35-39%.
10        Preferably, the potassium chloride solution has a mass fraction of 15-19%.
          Preferably, the 2-butylene-1,4-diacid solution has a mass fraction of 50-56%.
          Preferably, the mass fraction of p-xylene solution is 60-65%.
          Preferably, the mass fraction of dimethyl sulfone solution is 80-87%.
          Throughout the reaction process can be the following reaction formula:
                              0
                                    OH
                                       CH3
        Br                                                                        O
                                  +     C5H 02 + [(C2H 5 0)3P]4Ni                      OH
                             HCO
15             NH2
          Compared with the synthetic method disclosed in the background art, the
   invention     provides    4-pregnene-16a-       methyl-17a-mellow-3,    20-diketone    drug
   synthesis method, it is unnecessary to use the mixed solution of chromium oxide and
   sulfuric acid as reaction, avoiding the environmental pollution caused by chronic
20 oxide and the influence of high-risk chemicals on the safety factor caused by sulfuric
   acid, reducing intermediate links reaction, decreasing the reaction time and improving
   the reaction yield, at the same time, the present invention provides a new synthetic route
   which has laid a good foundation for further enhancing the yield of the reaction.

                                                   3
         DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
         The following examples with reference to specific embodiments of the present
   invention are further illustrated:
         Embodiment 1
 5       4-pregnene-16a-methyl-17u-mellow-3,         20-diketone  drug  synthesis method,
   comprises the following steps:
         A: 3mol 2-bromo-4-amino-5-pregnene-16a-methyl-3p , 17a-glycol-20-ketone,
   and 1.5 L potassium nitrate solution with a mass fraction of 10% were added to the
   reaction vessel, controlled the stirring speed at 110 rpm, raised the temperature of the
10 solution to 40"C, continued to react for 60min;
         B: added 6mol methyl butyric acid methyl ester solution with a mass fraction of 35%
   to react, raised the temperature of the solution to 50'C, continued to react for 30min,
   then added 2mol tetrakis (triethyl phosphite) nickel powder, refluxed for 30min,
   reduced the temperature of the solution to 30'C, added the oxalic acid solution, lay up
15 for hours to get hierarchical solution, washed with the potassium chloride solution
   with a mass fraction of 15% for three times, washed with 2-butylene-1,4-diacid
   solution with a mass fraction of 50% for five times, washed with the p-xylene solution
   with a mass fraction of 60% for six times, re-crystallized in the dimethyl sulfone
   solution with a mass fraction of 80%, dehydrated with anhydrous sodium sulfate
20 dehydration,    got the finished product           4-pregnene-16a-methyl-17a-mellow-3,
   20-diketone drug 895.23g, yield of 87%.
         Embodiment 2
         4-pregnene-16a-methyl-17a-mellow-3,         20-diketone  drug  synthesis method,
   comprises the following steps:
25       A: 3mol 2-bromo-4-amino-5-pregnene-16a-methyl-3p,            17a-glycol-20-ketone,
   and 1.5 L potassium nitrate solution with a mass fraction of 15% were added to the
   reaction vessel, controlled the stirring speed at 130 rpm, raised the temperature of the
   solution to 45 C, continued to react for 70min;

                                                   4
         B: added 6.5mol methyl butyric acid methyl ester solution with a mass fraction of
   37% to react, raised the temperature of the solution to 53 C,       continued to react for
   35min, then added 2.5mol tetrakis (triethyl phosphite) nickel powder, refluxed for
   40min, reduced the temperature of the solution to 34 0 C, added the oxalic acid solution,
 5 lay up for 1.5 hours to get hierarchical solution, washed with the potassium chloride
   solution with a mass fraction of 17% for four times, washed with 2-butylene-1,4-diacid
   solution with a mass fraction of 54% for six times, washed with the p-xylene solution
   with a mass fraction of 63% for eight times, re-crystallized in the dimethyl sulfone
   solution with a mass fraction of 82%, dehydrated with anhydrous calcium sulphate
10 dehydration,    got the    finished product        4-pregnene- 16a-methyl- I 7a-mellow-3,
   20-diketone drug 936.39g, yield of 91%.
         Embodiment 3
         4-pregnene-16a-methyl-17a-mellow-3,         20-diketone   drug   synthesis  method,
   comprises the following steps:
15       A: 3mol 2-bromo-4-amino-5-pregnene-16u-methyl-3p,             17a-glycol-20-ketone,
   and 1.5 L potassium nitrate solution with a mass fraction of 16% were added to the
   reaction vessel, controlled the stirring speed at 150 rpm, raised the temperature of the
   solution to 47"C,    continued to react for 80min;
         B: added 7mol methyl butyric acid methyl ester solution with a mass fraction of 39%
20 to react, raised the temperature of the solution to 56 0 C, continued to react for 40min,
   then added 3mol tetrakis (triethyl phosphite) nickel powder, refluxed for 50min,
   reduced the temperature of the solution to 36 0 C, added the oxalic acid solution, lay up
   for 2 hours to get hierarchical solution, washed with the potassium chloride      solution
   with a mass fraction of 19% for five times, washed with 2-butylene-1,4-diacid solution
25 with a mass fraction of 56% for seven times, washed with the p-xylene solution with a
   mass fraction of 65% for nine times, re-crystallized in the dimethyl sulfone solution
   with a mass fraction of 87%, dehydrated with anhydrous potassium carbonate
   dehydration,     got   the   finished   product    4-pregnene-16a-methyl-17u-mellow-3,

                                               5
  20-diketone drug 956.97g, yield of 93%.
       The embodiments of the present invention are merely preferred embodiments of
  the present invention, but the range of the present invention is not limited this, and
  any person who is familiar with those skilled in the arts, within the technical range of
5 the present invention. It is intended that the technical solution and its inventive
  concept be replaced or modified equivalently with reference to the range of the
  invention.

                                                 6
        Claims
         1. 4-pregnene-16a-methyl-17u-mellow-3, 20-diketone drug synthesis method,
   comprises the following steps:
 5      A: 2-bromo-4-amino-5-pregnene-16a-methyl-3p, 17a-glycol-20-ketone, and 1.5
   L potassium nitrate solution were added to the reaction vessel, controlled the stirring
   speed at 110-150 rpm, raised the temperature of the solution to 40-47 C, continued to
   react for 60-80 min;
        B: added butyric acid methyl ester solution to react, raised the temperature of the
10 solution to 50-56 C, continued to react for 30-40min, then added tetrakis (triethyl
   phosphite) nickel powder, refluxed for 30-50min, reduced the temperature of the
   solution to 30-36 C, added the oxalic acid solution, lay up for 1-2 hours to get
   hierarchical solution, washed with the potassium chloride solution for several times,
   washed with 2- butylene -1,4-diacid solution for several times, washed with the
15 p-p-xylene solution for several times, re-crystallized in the dimethyl sulfone solution,
   dehydrated        with      dehydration,       got       the       finished     product
   4-pregnene-16c-methyl-17a-mellow-3, 20-diketone drug.
        2. 4-pregnene-16a-methyl-1 7a-mellow-3, 20-diketone drug synthesis method
   according to claim 1 wherein potassium nitrate solution has a mass fraction of
20 10-16%.
        3. 4-pregnene-16a-methyl-17a-mellow-3,        20-diketone drug synthesis method
   according to claim 1 wherein the mass fraction of the butyric acid methyl ester
   solution is 35-39%.
        4. 4-pregnene-16u-methyl-1 7a-mellow-3, 20-diketone drug synthesis method
25 according to claim 1 wherein the potassium chloride solution has a mass fraction of
   15-19%.

